Indeed, by using the three inhibitors directed against AKT, mTORC1/2 and MEK1/2 we observed synergistic effects in vitro on cell viability of both MPNST cell lines analysed, in comparison to the dual AKT and mTORC1/2 treatment alone. The gene discussed is MAP2K1; the disease is malignant peripheral nerve sheath tumor.